Barclays reaffirmed their overweight rating on shares of AstraZeneca (LON:AZN) in a research note published on Tuesday.

A number of other equities analysts have also recently issued reports on the stock. Deutsche Bank upped their price objective on shares of AstraZeneca from GBX 6,000 ($78.40) to GBX 6,400 ($83.63) and gave the stock a buy rating in a research report on Monday, October 8th. Goldman Sachs Group set a GBX 4,080 ($53.31) price objective on shares of AstraZeneca and gave the stock a sell rating in a research report on Wednesday, September 26th. JPMorgan Chase & Co. set a GBX 6,500 ($84.93) price objective on shares of AstraZeneca and gave the stock a buy rating in a research report on Tuesday, September 25th. Citigroup reiterated a buy rating and set a GBX 6,200 ($81.01) price objective on shares of AstraZeneca in a research report on Tuesday, September 25th. Finally, UBS Group reiterated a neutral rating and set a GBX 5,900 ($77.09) price objective on shares of AstraZeneca in a research report on Tuesday, September 25th. Three research analysts have rated the stock with a sell rating, seven have given a hold rating and thirteen have given a buy rating to the company. The stock has a consensus rating of Hold and an average target price of GBX 5,700.70 ($74.49).

AZN stock opened at GBX 5,546 ($72.47) on Tuesday. AstraZeneca has a 1 year low of GBX 4,260 ($55.66) and a 1 year high of GBX 5,520 ($72.13).

About AstraZeneca

AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

Read More: What is the S&P 500 Index?

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.